# Contrast-enhanced Magnetic Resonance Imaging With Polysaccharide Superparamagnetic Iron Oxide Nanoparticle

> **NCT06010537** · EARLY_PHASE1 · COMPLETED · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 4 (actual)

## Conditions studied

- Magnetic Resonance Imaging

## Interventions

- **DRUG:** polysaccharide superparamagnetic iron oxide injection

## Key facts

- **NCT ID:** NCT06010537
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-28
- **Primary completion:** 2021-04-30
- **Final completion:** 2021-04-30
- **Target enrollment:** 4 (ACTUAL)
- **Last updated:** 2023-08-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06010537

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06010537, "Contrast-enhanced Magnetic Resonance Imaging With Polysaccharide Superparamagnetic Iron Oxide Nanoparticle". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT06010537. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*